Oncology

Over the next few years, undiagnosed breast cancer cases may add to the demand for more rigorous end-stage treatments and therapeutics.

Studies suggest novel immunotherapy may have efficacy as monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor.

Health care systems have made great strides by examining the diversity and equity of staffing.

Investigators found that treatment of high-grade squamous intraepithelial lesions in patients with HIV reduced anal cancer incidence by approximately 57%.

The findings of the phase 1b/2 CHRYSALIS-2 cohort will be presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer.

Study shows that adult survivors of cancer had a 42% greater risk of CVD than people who did not have the disease.

The drug combination demonstrated a 64.5% confirmed objective response rate in individuals with unresectable locally advanced or metastatic urothelial cancer who are ineligible to receive cisplatin-based chemotherapy.

The FDA is evaluating the use of adagrasib (MRTX849) to treat patients with non-small cell lung cancer harboring a KRAS G12C mutation who have previously received at least 1 systemic therapy.

Pirtobrutinib is under investigation in clinical trials in patients with CLL/small lymphocytic lymphoma, mantle cell lymphoma, and non-Hodgkin lymphoma.

With the vast number of drugs that can induce photosensitivity, patients taking any of these medications should receive safety counseling, especially during the summer months.

Trastuzumab deruxtecan is an engineered HER2-directed antibody drug conjugate being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

The panel concludes with their thoughts on the future of the AML treatment landscape.

Drs McCoy and McCloskey discuss relapsed/refractory AML, including treatment goals and options.

Progression-free survival was longer with brentuximab vedotin and fewer patients with Hodgkin lymphoma in this group received subsequent therapy.

The results showed a 38.1% confirmed objective response rate among HER2-positive patients who received tucatinib in combination with trastuzumab.

Poziotinib is an irreversible pan HER2 inhibitor with activity against mutations of HER1, HER2, and HER4.

Approximately one-third of the individuals had an intracranial response among those with central nervous system metastases.

Dronabinol (Syndros) is a cannabinoid indicated in adults for the treatment of: anorexia associated with weight loss in patients with AIDS and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Patients at highest risk of cancer recurrence, including people with lymph node-positive disease, saw the greatest reduction in the risk of recurrence or death with the pertuzumab-based regimen

Organizations such as the Appalachian Community Cancer Alliance are working to leverage technology and improve barriers to care.

Treatment's approval marks exciting new development for patients with ES-SCLC to prevent CIM.

This month, we spoke with Bob Luschen, PharmD, clinical coordinator for the pharmacy department at cancer Treatment Centers of America, Atlanta.

Cole McCoy, PharmD, considers if maintenance therapy is standard of care and what is involved with appropriate transitions upon discharge.

Cole McCoy, PharmD, details his experiences with oral maintenance therapies, specifically oral azacitidine.

About one-third of participants in the phase 1b cohort of the KRYSTAL-1 study show an intracranial response, according to Mirati Therapeutics.

The nature of CLL being a long-term, incurable disease makes its treatment a challenge as it is more focused toward improving patient’s quality of life.

With the rapid pace of change in biosimilar payer benefit design, efforts to stay regularly updated on policy changes ahead of time become critical for patient care.

Experts discuss the pros and cons of using oral azacytidine to treat patients with acute myeloid leukemia.

With a lack of head-to-head studies comparing combination regimens in frontline metastatic renal cell carcinoma, deciding on how to choose the right regimen can pose a challenge.

Crizotinib has also been approved to treat non-small cell lung cancer that has spread to other parts of the body and is caused by a defect in either the ALK or ROS1 gene.